Amelioration of Dextran Sodium Sulfate-Induced Colitis in Mice through Oral Administration of Palmitoylethanolamide
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice with dextran sodium sulfate (DSS)-induced experimental colitis
- Dose used in the study
- Palmitoylethanolamide encapsulated in phytosomes, at a human-equivalent dose of 123 mg/kg, once or twice daily, oral
- Duration
- Not stated in the abstract
- What was measured
- Clinical signs of colitis, gross mucosal injury, and leukocyte recruitment at inflamed venules, after oral phytosome-encapsulated PEA at a human-equivalent dose of 123 mg/kg, given once or twice daily.
What the authors reported
Palmitoylethanolamide reduced clinical signs of colitis, reduced gross mucosal injury and suppressed leukocyte recruitment at inflamed venules in DSS-induced experimental colitis.
Limits of this study
A mouse model of colitis; it cannot show effect in people with ulcerative colitis. One author received funding from MITACS, and three authors are former employees of Panag Pharma Inc.
Source
PubMed 38790962 · doi:10.3390/biomedicines12051000
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.